Effectiveness of Biologic Therapy in Controlling Inflammation and Achieving Disease Remission in Patients with Rheumatoid Arthritis: A Systematic Review
DOI:
https://doi.org/10.56183/iberojhr.v4i1.623Palavras-chave:
Rheumatoid arthritis; Biologic Therapy; inflammation controlResumo
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by joint pain, swelling, and potential systemic complications. The usefulness of biological treatments in reducing inflammation and helping RA patients achieve clinical remission is assessed in this systematic narrative review. Using PubMed, Scopus, and Google Scholar, a thorough literature search was carried out with an emphasis on research published in the last five years. The inclusion criteria were English-language human subject research that contributed significantly to our understanding of biological therapies for RA. Despite concerns over long-term drug withdrawal, TNF-alpha inhibitors, including certolizumab, adalimumab, and infliximab, have shown considerable effectiveness in lowering disease activity and inducing remission. Tocilizumab and other IL inhibitors have shown strong anti-inflammatory properties and increased rates of medication retention. Certain patient profiles have shown success with other biologics, such as rituximab and abatacept, especially those who have not responded to previous therapies. Empirical evidence demonstrates that tofacitinib, a JAK inhibitor, is just as effective as conventional biologics. The study emphasizes how important it is to create individualized treatment programs depending on the medical history and response to the condition. Even with encouraging findings, improving RA care requires ongoing observation of safety profiles and long-term effects. This study offers a thorough synthesis of the available data to help physicians choose the best biologic therapy for patients with RA.
Referências
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019). Strategies toward rheumatoid arthritis therapy; the old and the new. Journal of Cellular Physiology, 234(7), 10018–10031. https://doi.org/10.1002/JCP.27860
Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I., & Inderjeeth, C. A. (2021). The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies. The Journal of Rheumatology, 48(5), 669–676. https://doi.org/10.3899/JRHEUM.200367
Bird, P., Littlejohn, G., Butcher, B., Smith, T., da Fonseca Pereira, C., Witcombe, D., & Griffiths, H. (2020). Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 39(9), 2545–2551. https://doi.org/10.1007/S10067-020-05021-7
Choi, S., Ghang, B., Jeong, S., Choi, D., Lee, J. S., Park, S. M., & Lee, E. Y. (2021). Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting. Seminars in Arthritis and Rheumatism, 51(4), 685–691. https://doi.org/10.1016/J.SEMARTHRIT.2021.06.002
Cross, M., Smith, E., Hoy, D., Carmona, L., Wolfe, F., Vos, T., Williams, B., Gabriel, S., Lassere, M., Johns, N., Buchbinder, R., Woolf, A., & March, L. (2014). The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the Rheumatic Diseases, 73(7), 1316–1322. https://doi.org/10.1136/ANNRHEUMDIS-2013-204627
Crowson, C. S., Matteson, E. L., Myasoedova, E., Michet, C. J., Ernste, F. C., Warrington, K. J., Davis, J. M., Hunder, G. G., Therneau, T. M., & Gabriel, S. E. (2011). The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and Rheumatism, 63(3), 633–639. https://doi.org/10.1002/ART.30155
Curtis, J. R., Chakravarty, S. D., Black, S., Kafka, S., Xu, S., Langholff, W., Parenti, D., Greenspan, A., & Schwartzman, S. (2021). Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study. Rheumatology and Therapy, 8(4), 1551–1563. https://doi.org/10.1007/S40744-021-00354-4
Deane, K. D., Demoruelle, M. K., Kelmenson, L. B., Kuhn, K. A., Norris, J. M., & Holers, V. M. (2017). Genetic and environmental risk factors for rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 31(1), 3–18. https://doi.org/10.1016/J.BERH.2017.08.003
Ebina, K., Hirano, T., Maeda, Y., Yamamoto, W., Hashimoto, M., Murata, K., Takeuchi, T., Nagai, K., Son, Y., Amuro, H., Onishi, A., Jinno, S., Hara, R., Katayama, M., Yamamoto, K., Kumanogoh, A., & Hirao, M. (2020). Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. Clinical Rheumatology, 39(9), 2563–2572. https://doi.org/10.1007/S10067-020-05015-5
Ebina, K., Hirano, T., Maeda, Y., Yamamoto, W., Yamamoto, W., Hashimoto, M., Murata, K., Takeuchi, T., Shiba, H., Son, Y., Amuro, H., Onishi, A., Akashi, K., Hara, R., Katayama, M., Yamamoto, K., Kumanogoh, A., & Hirao, M. (2020). Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study. Arthritis Research and Therapy, 22(1). https://doi.org/10.1186/S13075-020-02232-W
Entezami, P., Fox, D. A., Clapham, P. J., & Chung, K. C. (2011). Historical Perspective on the Etiology of Rheumatoid Arthritis. Hand Clinics, 27(1), 1–10. https://doi.org/10.1016/j.hcl.2010.09.006
Gharaibeh, M., Bonafede, M., McMorrow, D., Maksabedian Hernandez, E. J., & Stolshek, B. S. (2020). Effectiveness and costs among rheumatoid arthritis patients treated with targeted immunomodulators using real-world U.S. data. Journal of Managed Care and Specialty Pharmacy, 26(8), 1039–1049. https://doi.org/10.18553/JMCP.2020.26.8.1039
Kawabe, A., Nakano, K., Miyata, H., Shibuya, R., Matsuyama, A., Ogoshi, T., & Tanaka, Y. (2019). Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. Internal Medicine, 58(4), 585–591. https://doi.org/10.2169/INTERNALMEDICINE.1280-18
Lauper, K., Nordström, D. C., Pavelka, K., Hernández, M. V., Kvien, T. K., Kristianslund, E. K., Santos, M. J., Rotar, Ž., Iannone, F., Codreanu, C., Lukina, G., Gale, S. L., Sarsour, K., Luder, Y., Courvoisier, D. S., & Gabay, C. (2018). Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: Analyses from the pan-European TOCERRA register collaboration. Annals of the Rheumatic Diseases, 77(9), 1276–1282. https://doi.org/10.1136/ANNRHEUMDIS-2017-212845
Littlejohn, E. A., & Monrad, S. U. (2018). Early Diagnosis and Treatment of Rheumatoid Arthritis. Primary Care - Clinics in Office Practice, 45(2), 237–255. https://doi.org/10.1016/j.pop.2018.02.010
Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010). Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis and Rheumatism, 62(6), 1576–1582. https://doi.org/10.1002/ART.27425
Nikfar, S., Saiyarsarai, P., Tigabu, B. M., & Abdollahi, M. (2018). Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology International, 38(8), 1363–1383. https://doi.org/10.1007/S00296-018-4041-1/METRICS
Patel, J. P., Konanur Srinivasa, N. K., Gande, A., Anusha, M., Dar, H., & Baji, D. B. (2023). The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. Cureus, 15(1). https://doi.org/10.7759/CUREUS.33293
Patel, J. P., Srinivasa, N. K. K., Gande, A., Anusha, M., Dar, H., & Baji, D. B. (2023). The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. Cureus, 15(1). https://doi.org/10.7759/CUREUS.33293
Pérez-Sánchez, C., Cecchi, I., Barbarroja, N., Patiño-Trives, A. M., Luque-Tévar, M., Pérez-Sánchez, L., Ibáñez-Costa, A., Arias de la Rosa, I., Ortega, R., Escudero, A., Castro, M. C., Radin, M., Roccatello, D., Sciascia, S., Aguirre, M. Á., Collantes, E., & López-Pedrera, C. (2019). Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. Journal of Cellular and Molecular Medicine, 23(9), 6308–6318. https://doi.org/10.1111/JCMM.14517
Radner, H., & Aletaha, D. (2015). Anti-TNF in rheumatoid arthritis: an overview. Wiener Medizinische Wochenschrift (1946), 165(1–2), 3–9. https://doi.org/10.1007/S10354-015-0344-Y
Rahman, P., Baer, P., Keystone, E., Choquette, D., Thorne, C., Haraoui, B., Chow, A., Faraawi, R., Olszynski, W., Kelsall, J., Rampakakis, E., Lehman, A. J., & Nantel, F. (2020). Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. BMC Rheumatology, 4(1). https://doi.org/10.1186/S41927-020-00145-4
Stanford, S. M., & Bottini, N. (2014). PTPN22: the archetypal non-HLA autoimmunity gene. Nature Reviews Rheumatology 2014 10:10, 10(10), 602–611. https://doi.org/10.1038/nrrheum.2014.109
Sung, Y. K., & Lee, Y. H. (2021). Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacology and Therapeutics, 59(9), 618–626. https://doi.org/10.5414/CP204017
Ursini, F., Leporini, C., Bene, F., D’Angelo, S., Mauro, D., Russo, E., De Sarro, G., Olivieri, I., Pitzalis, C., Lewis, M., & Grembiale, R. D. (2017). Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Scientific Reports 2017 7:1, 7(1), 1–10. https://doi.org/10.1038/s41598-017-05759-2
Vander Cruyssen, B., Hoffman, I. E. A., Peene, I., Union, A., Mielants, H., Meheus, L., & De Keyser, F. (2007). Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Annals of the Rheumatic Diseases, 66(3), 364–369. https://doi.org/10.1136/ARD.2006.053470
You, Y., Stelzl, P., Joseph, D. N., Aldo, P. B., Maxwell, A. J., Dekel, N., Liao, A., Whirledge, S., & Mor, G. (2021). TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion. Frontiers in Immunology, 12, 737401. https://doi.org/10.3389/FIMMU.2021.737401/BIBTEX
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Josselin Alejandra Villacrés Vega, Lisbeth Paola Guamán Punguil, Sergio Andres Maila Zuñiga, Isamar Pamela Castro Lahuasi, Angelica Marina Basantes Castillo, Gabriela Rebeca Yanez García, Nathaly Marie Yepez Alcivar
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
